TIAL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Because CML chemoresistance is attributed to acquiring of quiescence in the BMM,1 TIAR and FMRP activity could essentially modify leukemia cells’ sensitivity to therapy.